Marcucci Francesco, Sensi Laura, Incorvaia Cristoforo, Dell'Albani Ilaria, Di Cara Giuseppe, Frati Franco
Spin-Off ATRP Srl, Allergic Tests Research and Production, Perugia, Italy.
Clin Mol Allergy. 2012 Jun 13;10(1):7. doi: 10.1186/1476-7961-10-7.
Grass pollen is a major cause of respiratory allergy worldwide and contain a number of allergens, some of theme (Phl p 1, Phl p 2, Phl p 5, and Phl 6 from Phleum pratense, and their homologous in other grasses) are known as major allergens. The administration of grass pollen extracts by immunotherapy generally induces an initial rise in specific immunoglobulin E (sIgE) production followed by a progressive decline during the treatment. Some studies reported that immunotherapy is able to induce a de novo sensitisation to allergen component previously unrecognized.
We investigated in 30 children (19 males and 11 females, mean age 11.3 years), 19 treated with sublingual immunotherapy (SLIT) by a 5-grass extract and 11 untreated, the sIgE and sIgG4 response to the different allergen components.
Significant increases (p < 0.001) were detected for Phl p 1, Phl p 2, Phl p 5, and Phl p 6, while sIgE levels induced in response to Phl p 7 and Phl p 12 were low or absent at baseline and unchanged following SLIT treatment; no new sensitisation was detected. As to IgG4, significant increases were found for Phl p2 and Phl p 5, while the increase for Phl p 12 was not significant. In the control group, no significant increase in sIgE for any single allergen component was found.
These findings confirm that the initial phase of SLIT with a grass pollen extract enhances the sIgE synthesis and show that the sIgE response concerns the same allergen components which induce IgE reactivity during natural exposure.
草花粉是全球呼吸道过敏的主要诱因,含有多种过敏原,其中一些(来自早熟禾的Phl p 1、Phl p 2、Phl p 5和Phl p 6,以及其他草类中的同源物)被认为是主要过敏原。通过免疫疗法给予草花粉提取物通常会导致特异性免疫球蛋白E(sIgE)产生最初上升,随后在治疗过程中逐渐下降。一些研究报告称,免疫疗法能够诱导对先前未识别的过敏原成分产生从头致敏。
我们调查了30名儿童(19名男性和11名女性,平均年龄11.3岁),其中19名接受了5种草提取物的舌下免疫疗法(SLIT)治疗,11名未接受治疗,检测了他们对不同过敏原成分的sIgE和sIgG4反应。
检测到Phl p 1、Phl p 2、Phl p 5和Phl p 6有显著增加(p < 0.001),而对Phl p 7和Phl p 12的sIgE水平在基线时较低或不存在,SLIT治疗后未发生变化;未检测到新的致敏情况。关于IgG4,Phl p2和Phl p 5有显著增加,而Phl p 12的增加不显著。在对照组中,未发现任何单一过敏原成分的sIgE有显著增加。
这些发现证实了草花粉提取物舌下免疫疗法的初始阶段会增强sIgE合成,并表明sIgE反应涉及自然暴露期间诱导IgE反应性的相同过敏原成分。